Literature DB >> 9535991

Agonist-induced desensitization and down-regulation of the human kappa opioid receptor expressed in Chinese hamster ovary cells.

J Zhu1, L Y Luo, G F Mao, B Ashby, L Y Liu-Chen.   

Abstract

In this study, we examined whether the human kappa opioid receptor stably expressed in Chinese hamster ovary cells underwent desensitization and down-regulation after prolonged exposure to the agonist (-)U50,488H. Pretreatment with (-)U50,488H led to a reduction in the magnitude of increase in [35S]GTPgammaS binding by the subsequent application of (-)U50,488H. The extent of desensitization was related to duration of exposure and (-)U50,488H concentration. Pretreatment with (-)U50,488H also reduced the potency of (-)U50,488H in inhibiting forskolin-stimulated adenylate cyclase. In membranes of (-)U50,488H-pretreated cells, the affinity of (-)U50,488H was lower than that in the untreated control, and GTPgammaS had no effect on (-)U50,488H affinity, consistent with the notion of uncoupling of the receptor-G protein complex by (-)U50, 488H treatment. Down-regulation of the kappa opioid receptor also occurred on exposure to (-)U50,488H. Higher (-)U50,488H concentrations and/or longer incubation periods were required for down-regulation than for desensitization. The degree of down-regulation depended on the agonist concentration and incubation time. (-)U50,488H-induced desensitization and down-regulation were blocked by naloxone. (+)U50,488H, an inactive stereoisomer, did not cause desensitization or down-regulation. These results indicate that both processes were receptor-mediated. After incubation with (-)U50,488H and removal of (-)U50,488H, both (-)U50,488H-induced [35S]GTPgammaS binding and receptor number returned to the control level, which indicates that both processes were reversible. Thus, desensitization and down-regulation of the kappa opioid receptor occur after agonist exposure and represent two different adaptation mechanisms.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9535991

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  5 in total

1.  Cholesterol reduction by methyl-beta-cyclodextrin attenuates the delta opioid receptor-mediated signaling in neuronal cells but enhances it in non-neuronal cells.

Authors:  Peng Huang; Wei Xu; Su-In Yoon; Chongguang Chen; Parkson Lee-Gau Chong; Lee-Yuan Liu-Chen
Journal:  Biochem Pharmacol       Date:  2006-11-03       Impact factor: 5.858

2.  Role of protein kinase C-epsilon in the development of kappa-opioid receptor tolerance to U50,488H in rat ventricular myocytes.

Authors:  Jing-Jun Zhou; Jin-Song Bian; Jian-Ming Pei; Song Wu; Hong-Yu Li; Tak-Ming Wong
Journal:  Br J Pharmacol       Date:  2002-04       Impact factor: 8.739

3.  Agonist-promoted Lys63-linked polyubiquitination of the human kappa-opioid receptor is involved in receptor down-regulation.

Authors:  Jian-Guo Li; Dale S Haines; Lee-Yuan Liu-Chen
Journal:  Mol Pharmacol       Date:  2008-01-22       Impact factor: 4.436

Review 4.  Opioid receptor desensitization: mechanisms and its link to tolerance.

Authors:  Stéphane Allouche; Florence Noble; Nicolas Marie
Journal:  Front Pharmacol       Date:  2014-12-18       Impact factor: 5.810

5.  Quantification of kappa opioid receptor ligand potency, efficacy and desensitization using a real-time membrane potential assay.

Authors:  Yuanzi Zhao; Anand A Joshi; Jane V Aldrich; Thomas F Murray
Journal:  Biomed Pharmacother       Date:  2021-09-15       Impact factor: 6.529

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.